The U.S. growth acceleration to 13% (from ~1.5% last quarter) confirms the MiniMed Flex launch is driving a step-change in domestic market share. With guidance raised and a strong pipeline (MiniMed Fit, Vivera FCL, extended-wear sensor), the stock should re-rate higher. Monitor Q2 for sustained U.S. NPS growth and CGM attachment rate progression above 70%.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 1 $22.42entry
- T+1 · 3mo ago +5.98%α +5.53% · $23.76
- T+5 · 2mo ago +1.52%α +1.44% · $22.76
- T+20 · 7w ago −11.65%α −12.83% · $19.81
- T+53 · todayOpen
- T+60 · in 8d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
MiniMed reported Q1 FY27 net sales of $843M (+16.6% YoY as reported, +15.8% organic), with U.S. growth accelerating to 13.1% and international up 18.1%. The company raised FY27 organic revenue growth guidance to ~10.5% from ~10%, while reaffirming ~16% adjusted EBITDA margin. GAAP EPS was $0.00, essentially breakeven vs a loss of -$0.08 a year ago, but this is a medical device company where the Street focuses on revenue growth and pipeline catalysts, not GAAP EPS.
Key Financial Metrics
Key Facts
- Worldwide net sales of $843M grew 16.6% as reported and 15.8% organic
- U.S. net sales grew 13.1% YoY, accelerating from 1.5% in Q4 FY26, driven by MiniMed Flex launch
- U.S. New Pumps Sold grew over 20% YoY
- FY27 organic revenue growth guidance raised to ~10.5% from ~10%
- MiniMed Fit patch pump submitted to FDA; MiniMed Flex received CE Mark; Vivera FCL pivotal trial enrollment complete
- GAAP net income attributable to the Company was approximately $0 (breakeven) vs a loss of $19M in the prior year period
- GAAP EPS was $0.00 vs -$0.08 in Q1 FY26
Financial Impact
Q1 net sales of $843M, up 16.6% YoY; FY27 organic revenue guidance raised to ~10.5%
Risk Factors
- GAAP profitability remains near zero; adjusted EBITDA margin guidance of ~16% leaves limited margin of safety if growth decelerates
- Extra week benefit (~4-6%) in Q1 will not repeat in subsequent quarters
- Competitive pressure from Dexcom G7 and Tandem Mobi could slow U.S. market share gains
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-059699 |
| Document: mmed-20260901.htm | 0001628280-26-059699 |
| Document: 0001628280-26-059699-index-headers.html | 0001628280-26-059699 |
| Document: 0001628280-26-059699-index.html | 0001628280-26-059699 |
| Document: 0001628280-26-059699.txt | 0001628280-26-059699 |
| 8-K Data (Synthetic) | 0001628280-26-059699 |
Track record
25 reports on MMED
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today 8-K Mixed 6/10 Entry $18.77 Now $18.65 −0.64% settles Dec 15
- Nov 16, 2026today Press Release Bullish 7/10 Entry $18.81 Now $18.65 −0.86% settles Dec 15
- Nov 6, 202610d ago SC 13G Neutral 4/10 Entry $16.71 Now $18.65 +11.61% settles Dec 7
- Oct 22, 202625d ago SC 13G Neutral 4/10 Entry $18.34 Now $18.65 +1.69% settles Nov 20
- Oct 16, 20264w ago SC 13G/A Neutral 4/10 Entry $17.79 to $18.65 Now $18.65 +4.83% ▲ +4.83% +8.30% vs SPY
- Oct 16, 20264w ago 8-K Neutral 6/10 Entry $17.49 to $17.99 Now $18.65 +6.63% ▲ +2.86% +4.02% vs SPY
- Oct 6, 20265w ago EFFECT Neutral 3/10 Entry $19.64 to $18.85 Now $18.65 −5.04% ▼ −4.02% −0.85% vs SPY
- Oct 1, 20266w ago 3 Neutral 2/10 Entry $19.70 to $18.28 Now $18.65 −5.33% ▼ −7.21% −5.40% vs SPY
- Sep 14, 20269w ago 425 Neutral 4/10 Entry $21.97 to $18.80 Now $18.65 −15.11% ▼ −14.43% −16.69% vs SPY
- Sep 14, 20269w ago 425 Neutral 4/10 Entry $21.97 to $18.80 Now $18.65 −15.11% ▼ −14.43% −16.69% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers